Myriad Genetics, Inc. MYGN
5.54 USD +0.01 (+0.18%)
Regular-session close
5.54 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
5.44 Day range 5.74
2.86 52-week range 7.91
- YTD
- -9.92%
- 1 year
- -13.98%
News
benzinga.com BillionToOne Faces Short Report Alleging Kickbacks, Flawed Diagnostic Tests Short seller Fuzzy Panda accuses BillionToOne of undisclosed Medicaid fraud, illegal kickbacks, and flawed tests in a scathing new report.benzinga.com Myriad Genetics Expands Collaboration With SRL To Enable Local Japanese Testing For Its BRACAnalysis Diagnostic System The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.Local…
globenewswire.com Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth SALT LAKE CITY, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces an expansion of its…benzinga.com Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6 Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.
seekingalpha.com Myriad Genetics, Inc. (MYGN) Presents at 2026 UBS Global Healthcare Conference Transcript Myriad Genetics, Inc. ( MYGN ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal…benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4.5 to $6.75.
benzinga.com Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8 Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.
seekingalpha.com Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript Myriad Genetics, Inc. ( MYGN ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO &…
zacks.com Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates Myriad Genetics (MYGN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to break-even earnings per share a year ago.
marketbeat.com Myriad Genetics Q3 Earnings Call Highlights Myriad Genetics NASDAQ: MYGN reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal…
benzinga.com Myriad Genetics Q3 2026 Earnings Call Transcript Myriad Genetics (NASDAQ:MYGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Myriad Genetics Raises FY2026 Sales Guidance from $770.000M-$790.000M to $780.000M-$790.000M vs $777.921M Est Myriad Genetics (NASDAQ:MYGN) raises FY2026 sales outlook from $770.000 million-$790.000 million to $780.000 million-$790.000 million vs $777.921 million estimate.
benzinga.com Myriad Genetics Q3 Adj. EPS $(0.11) Beats $(0.20) Estimate, Sales $202.700M Beat $191.329M Estimate Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. The company reported quarterly sales of $202.700…
globenewswire.com Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued…
globenewswire.com Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will…
globenewswire.com Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valued at $210 million, plus the value of…
benzinga.com Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
benzinga.com Nasdaq Rises Over 100 Points; 3M Earnings Top Views U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.
benzinga.com Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.benzinga.com Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
globenewswire.com Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a…
globenewswire.com Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings…
defenseworld.net ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
prnewswire.com SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic…
globenewswire.com Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)…defenseworld.net Applied Dna Sciences (NASDAQ:BNBX) and Myriad Genetics (NASDAQ:MYGN) Head to Head Analysis Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the…
globenewswire.com Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been…
barrons.com This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
globenewswire.com Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present…
businesswire.com MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the…
defenseworld.net Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN Dimensional Fund Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 42.6% during the first quarter, according to the company in its most recent Form 13F filing with…
